Results
1 -
10 of
17Rye Carl S., Chessum Nicola E. A., Lamont Scott, Pike Kurt G., Faulder Paul, Demeritt Julie, Kemmitt Paul, Tucker Julie, Zani Lorenzo, Cheeseman Matthew D., Isaac Rosie, Goodwin Louise, Boros Joanna, Raynaud Florence, Hayes Angela, Henley Alan T., de Billy Emmanuel, Lynch Christopher J., Sharp Swee Y., te Poele Robert, Fee Lisa O’, Foote Kevin M., Green Stephen, Workman Paul, Jones Keith.
Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9, Med. Chem. Commun., 2016 Olson et al.
Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation.
Nature Chemical Biology, doi: 10.1038/nchembio.2538, published online 18 December 2017 The CDK inhibitors in cancer research and therapy, Journal of Cancer Research and Clinical Oncology CDK Inhibitors as Anticancer Agents, Checkpoint Responses in Cancer Therapy Targeting Cyclin-Dependent Kinases with Small Molecule Inhibitors, Checkpoint Controls and Targets in Cancer Therapy Regulation of p53 Activity and Associated Checkpoint Controls, Checkpoint Controls and Targets in Cancer Therapy CDK Inhibitors in Multiple Myeloma, Myeloma Therapy Cyclin-Dependent Kinase Modulators and Cancer Therapy, BioDrugs Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro, Cancer Chemotherapy and Pharmacology SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples, Cancer Chemotherapy and Pharmacology